Research ArticleConference Proceedings

Aerosol Delivery Devices for Obstructive Lung Diseases

Roy A Pleasants and Dean R Hess
Respiratory Care June 2018, 63 (6) 708-733; DOI: https://doi.org/10.4187/respcare.06290

References

  1. 1.↵
    1. Stein SW,
    2. Thiel CG
    . The history of therapeutic aerosols: a chronological review. J Aerosol Med Pulm Drug Deliv 2017;30(1):20–41.
    OpenUrl
  2. 2.↵
    1. Sanchis J,
    2. Gich I,
    3. Pedersen S
    . Systematic review of errors in inhaler use. Has patient technique improved over time? Chest 2016;150(2):394–406.
    OpenUrlPubMed
  3. 3.↵
    1. Laube BL,
    2. Janssens HM,
    3. de Jong FHC,
    4. Devadason FG,
    5. Dhand R,
    6. Everhard ML,
    7. et al
    . ERS/ISAM Task Force Report. What the pulmonologist should know about new inhalational therapies. Eur Respir J 2011;37(6):1308–1331.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Nahar K,
    2. Gupta N,
    3. Gauvin R,
    4. Absar S,
    5. Patel B,
    6. Gupta V,
    7. et al
    . In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals. Eur J Pharmaceutical Sci 2013;49(5):805–818.
    OpenUrl
  5. 5.↵
    1. Corcoran TE
    . Imaging in aerosol medicine. Respir Care 2015;60(6):850–857.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Thompson RB,
    2. Finlay WH
    . Using MRI to measure aerosol deposition. J Aerosol Med Pulmon Drug Deliv 2012;25(2):55–62.
    OpenUrl
  7. 7.↵
    1. Newman SP,
    2. Steed KP,
    3. Reader SJ
    . Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J Pharm Sci 1996;85(9):960–964.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Kirby M,
    2. Mathew L,
    3. Heydarian M,
    4. McCormack DG,
    5. Etemad-Rezai R,
    6. Parraga G
    . Chronic obstructive pulmonary disease: quantification of bronchodilator effects by using hyperpolarized 3 He MR imaging. Radiology 2011;261(1):283–292.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Lipworth BJ
    . Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol 1996;42(6):697–705.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Mortensen NP,
    2. Hickey AJ
    . Targeting inhaled therapy beyond the lungs. Respiration 2014;88(5):353–364.
    OpenUrl
  11. 11.↵
    1. Lavorini F,
    2. Pedersen S,
    3. Usmani OS
    . Dilemmas, confusion, and misconceptions: related to small airways directed therapy. Chest 2017;151(6):1345–1355.
    OpenUrl
  12. 12.↵
    1. Smyth HDC,
    2. Hickey AJ
    1. Olsson B,
    2. Bondesson E,
    3. Bongstrom L,
    4. Edsbäcker S,
    5. Eirefelt S,
    6. Ekelund K,
    7. Gustavsson L,
    8. Hegelund-Myrbäck T
    . Pulmonary drug metabolism, clearance, and absorption. In: Controlled Pulmonary Drug Delivery, eds Smyth HDC, Hickey AJ. New York: Springer; 2011;21–50.
  13. 13.↵
    1. Kobrich R,
    2. Rudolf G,
    3. Stahlhofen W
    . A mathematical model of mass deposition in man. Ann Occup Hyg 1994;38(Suppl 1):15–23.
    OpenUrlCrossRef
  14. 14.↵
    1. Labiris NR,
    2. Dolovich MB
    . Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56(6):588–599.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Schamberger AC,
    2. Mise N,
    3. Jia J,
    4. Genoyer E,
    5. Yildirim AÖ,
    6. Meiners S,
    7. Eickelberg O
    . Cigarette smoke-induced disruption of bronchial epithelial tight junctions is prevented by transforming growth factor-β. Am J Respir Cell Mol Biol 2014;50(6):1040–1052.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Roberts JK,
    2. Moore CD,
    3. Ward RM,
    4. Yost GM,
    5. Reilly CA
    . Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymes. J Pharmacol Exp Ther 2013;345(2):308–316.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Hess DR
    . Aerosol delivery devices in the treatment of asthma. Respir Care 2008;53(6):699–723.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Dolovich MB,
    2. Ahrens RC,
    3. Hess DR,
    4. Anderson P,
    5. Dhand R,
    6. Ray JL,
    7. et al
    . Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest 2005;127(1):335–371.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Newman SP
    . Principles of metered-dose inhaler design. Respir Care 2005;50(9):1177–1190.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Hou S,
    2. Wu J,
    3. Li X,
    4. Shu H
    . Practical, regulatory and clinical considerations for development of inhalation drug products. Asian J Pharm Sci 2015;10(8):490–500.
    OpenUrl
  21. 21.↵
    1. Ferguson G,
    2. Hickey AJ,
    3. Dwivedi S
    . Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases. Respir Med 2018;134:16–23.
    OpenUrl
  22. 22.↵
    1. Dalby RN,
    2. Eicher J,
    3. Zierneberg B
    . Development of Respimat Soft Mist inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl) 2011;4:145–55.
    OpenUrl
  23. 23.↵
    1. Pitcairn G,
    2. Reader S,
    3. Pavia D,
    4. Newman S
    . Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared with deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med 2005;18(3):264–272.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Anderson P
    . Use of Respimat Soft Mist inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis 2006;1(3):251–259.
    OpenUrlPubMed
  25. 25.↵
    Spiriva Respimat Product Insert. Boehringer Ingelheim: Connnecticut; 2017.
  26. 26.↵
    1. Newman SP,
    2. Newhouse MT
    . Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects. J Aerosol Med 1996;9(1):55–70.
    OpenUrlPubMedWeb of Science
  27. 27.↵
    1. Dissanayake S,
    2. Suggett J
    . A review of the in vitro and in vivo valved holding chamber (VHC) literature with a focus on the AeroChamber Plus Flow-Vu Anti-static VHC. Ther Adv Respir Dis 2018;12:1–14.
    OpenUrl
  28. 28.↵
    1. Clark DJ,
    2. Lipworth BJ
    . Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device. Thorax 1996;51(10):981–984.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Slator L,
    2. von Hollen D,
    3. Sandell D,
    4. Hatley RHM
    . In vitro comparison of the effect of inhalation delay and flow rate on the emitted dose from three valved holding chambers. J Aerosol Med Pulmon Drug Deliv 2014;27(Suppl 1):S37–S43.
    OpenUrl
  30. 30.↵
    1. Leach CL,
    2. Colice GL
    . A pilot study to assess lung deposition of HFA-beclomethasone and CFC-beclomethasone from a pressurized metered dose inhaler with and without add-on spacers and using varying breathhold times. J Aerosol Pulm Drug Deliv 2010;23(6):355–361.
    OpenUrl
  31. 31.↵
    1. Singh D,
    2. Collarini S,
    3. Poli G,
    4. Acerbi D,
    5. Amadasi A,
    6. Rusca A
    . Effect of AeroChamber Plus on the lung and systemic bioavailability of beclomethasone dipropionate/formoterol pMDI. Br J Clin Pharmacol 2011;72(6):932–939.
    OpenUrlPubMed
  32. 32.↵
    1. Anhoj J,
    2. Bisgaard H,
    3. Lipworth BJ
    . Effect of electrostatic charge in plastic spacers on the lung delivery of HFA-salbutamol in children. Br J Clin Pharmacol 1999;47(3):333–336.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    1. Wildhaber JH,
    2. Waterer GW,
    3. Hall GL,
    4. Summers QA
    . Reducing electrostatic charge on spacer devices and bronchodilator response. Br J Clin Pharmacol 2000;50(3):277–280.
    OpenUrlPubMedWeb of Science
  34. 34.↵
    1. Dal Nagro RW
    . Dry powder inhalers and the right things to remember: a concept review Multidisc Respir Med 2015;10(1):13.
  35. 35.↵
    1. Mahler DA
    , Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann Amer Thorac Soc 2017;14(7):1103–1107.
    OpenUrl
  36. 36.↵
    1. Ghosh S,
    2. Ohar JA,
    3. Drummond MB
    . Peak inspiratory flow rate in chronic obstructive pulmonary disease: implications for dry powder inhalers. J Aerosol Med Pulm Drug Deliv 2017;30(6):1–7.
    OpenUrl
  37. 37.↵
    1. Kikidis D,
    2. Konstantinos V,
    3. Tzovaras D,
    4. Usmani OS
    . The digital asthma patient: the history and future of inhaler-based health monitoring devices. J Aerosol Med Pulmon Drug Deliv 2016;29(3):219–232.
    OpenUrl
  38. 38.↵
    1. Carpenter DM,
    2. Roberts CA,
    3. Sage AJ,
    4. George J,
    5. Horne R
    . A review of electronic devices to assess inhaler technique. Curr Allergy Asthma Rep 2017;17(3):17.
    OpenUrl
  39. 39.↵
    1. Kim MS,
    2. Henderson KA,
    3. Sickle DV
    . Using connected devices to monitor inhaler use in the real world. Respir Drug Deliv 2016;1:37–44.
    OpenUrl
  40. 40.↵
    1. Fan VS,
    2. Gyly-Colwell I,
    3. Locke E,
    4. Sumino K,
    5. Ngyyen HQ,
    6. Thomas RM,
    7. Magzame S
    . Overuse of short-acting beta-agonist bronchodilators in COPD during periods of clinical stability. Respir Med 2016;116(7):100–106.
    OpenUrl
  41. 41.↵
    1. Merchant RK,
    2. Inamdar R,
    3. Quade RC
    . Effectiveness of population health management using the propeller health asthma platform: a randomized clinical trial. J Allergy Clin Immunol Pract 2016;4(3):455–463.
    OpenUrl
  42. 42.↵
    1. Seheult JN,
    2. Costello S,
    3. Tee KC,
    4. et al
    . Investigating the relationship between peak inspiratory flow rate and volume of inhalation from a Diskus Inhaler and baseline spirometric parameters: a cross-sectional study. Springerplus 2014;2(3):496.
    OpenUrl
  43. 43.↵
    1. Seheult JN,
    2. O'Connell P,
    3. Tee KC,
    4. Bholah T,
    5. Al Bannai H,
    6. Sulaiman I,
    7. et al
    . The acoustic features of inhalation can be used to quantify aerosol delivery from a Diskus dry powder inhaler. Pharm Res 2014;31:2735–2747.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Sulaiman I,
    2. Seheult J,
    3. Sadasivuni N,
    4. Bholah T,
    5. Al Bannai H,
    6. Sulaiman I,
    7. et al
    . The impact of common inhaler errors on drug delivery: investigating critical errors with a dry powder inhaler. J Aerosol Med Pulm Drug Deliv 2017;30(10):247–255.
    OpenUrl
  45. 45.↵
    1. Sulaiman I,
    2. Cushan B,
    3. Greene G,
    4. Seheult J,
    5. Seow D,
    6. Rawat F,
    7. et al
    . Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017;195(10):1333–1343.
    OpenUrl
  46. 46.↵
    1. Sulaiman I,
    2. Greene G,
    3. MacHale E,
    4. Seheult J,
    5. Mokoka M,
    6. D'Arcy SD,
    7. et al
    . A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma. Eur Respir J 2018;51(1):1701126.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Everhard ML,
    2. Evans M,
    3. Milner AD
    . Is tapping jet nebulizers worthwhile? Arch Dis Child 1994;70(6):538–539.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Malone RA,
    2. Hollie MC,
    3. Glynn-Barnhart A,
    4. Nelson HS
    . Optimal duration of nebulized albuterol therapy. Chest 1993;104(4):1114–1118.
    OpenUrlPubMedWeb of Science
  49. 49.↵
    1. Hess D,
    2. Fisher D,
    3. Williams P,
    4. Pooler S,
    5. Kacmarek RM
    . Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. Chest 1996;110(2):498–505.
    OpenUrlCrossRefPubMedWeb of Science
  50. 50.↵
    1. Terzano C,
    2. Petroianni A,
    3. Parola D,
    4. Ricci A
    . Compressor/nebulizers differences in the nebulization of corticosteroids. The CODE study (Corticosteroids and Devices Efficiency). Eur Rev Med Pharmacol Sci 2007;11(4):225–237.
    OpenUrlPubMed
  51. 51.↵
    1. Waldrep JC,
    2. Keyhani K,
    3. Black M,
    4. Knight V
    . Operating characteristics of 18 different continuous-flow jet nebulizers with beclomethasone dipropionate liposome aerosol. Chest 1994;105(1):106–110.
    OpenUrlCrossRefPubMedWeb of Science
  52. 52.↵
    1. Awad SW,
    2. Berlinski A
    . Crossover evaluation of compressors and nebulizers typically used by cystic fibrosis patients. Respir Care 2018;63 (3) 294–300.
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    1. Awad S,
    2. Williams DK,
    3. Berlinski A
    . Longitudinal evaluation of compressor/nebulizer performance. Respir Care 2014;59(7):1053–1061.
    OpenUrlAbstract/FREE Full Text
  54. 54.↵
    1. Reisner C,
    2. Katial RK,
    3. Bartelson BB,
    4. Buchmeir A,
    5. Rosenwasser LJ,
    6. Nelson HS
    . Characterization of aerosol output from various nebulizer/compressor combinations. Ann Allergy Asthma Immunol 2001;86(5):566–574.
    OpenUrlPubMedWeb of Science
  55. 55.↵
    1. Standaert TA,
    2. Bohn SE,
    3. Aitken ML,
    4. Ramsey B
    . The equivalence of compressor pressure-flow relationships with respect to jet nebulizer aerosolization characteristics. J Aerosol Med 2001;14(1):31–42.
    OpenUrlPubMed
  56. 56.↵
    1. Everard ML,
    2. Hardy JG,
    3. Milner AD
    . Comparison of nebulized aerosol deposition in the lungs of healthy adults following oral and nasal inhalation. Thorax 1993;48(10):1045–1046.
    OpenUrlAbstract/FREE Full Text
  57. 57.↵
    1. Nikander K,
    2. Agertoft L,
    3. Pedersen S
    . Breath-synchronized nebulization diminishes the impact of patient-device interfaces (face mask or mouthpiece) on the inhaled mass of nebulized budesonide. J Asthma 2000;37(5):451–459.
    OpenUrlPubMed
  58. 58.↵
    1. Kishida M,
    2. Suzuki I,
    3. Kabayama H,
    4. Koshibu T,
    5. Izawa M,
    6. Takeshita Y,
    7. et al
    . Mouthpiece versus facemask for delivery of nebulized salbutamol in exacerbated childhood asthma. J Asthma 2002;39(4):337–339.
    OpenUrlCrossRefPubMed
  59. 59.↵
    1. Kohler E,
    2. Sollich V,
    3. Schuster-Wonka R,
    4. Huhnerbein J,
    5. Jorch G
    . Does wearing a noseclip during inhalation improve lung deposition? J Aerosol Med 2004;17(2):116–122.
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.↵
    1. Meier R,
    2. Hall GL,
    3. Sennhauser FH,
    4. Wildhaber JH
    . Wearing a noseclip improves nebulised aerosol delivery. Swiss Med Wkly 2001;131(33-34):495–497.
    OpenUrlPubMed
  61. 61.↵
    1. Bisquerra RA,
    2. Botz GH,
    3. Nates JL
    . Ipratropium-bromide-induced acute anisocoria in the intensive care setting due to ill-fitting face masks. Respir Care 2005;50(12):1662–1664.
    OpenUrlFREE Full Text
  62. 62.
    1. Brodie T,
    2. Adalat S
    . Unilateral fixed dilated pupil in a well child. Arch Dis Child 2006;91(12):961.
    OpenUrlFREE Full Text
  63. 63.
    1. Erzinger S,
    2. Schueepp KG,
    3. Brooks-Wildhaber J,
    4. Devadason SG,
    5. Wildhaber JH
    . Facemasks and aerosol delivery in vivo. J Aerosol Med 2007;20(Suppl 1):S78–S84.
    OpenUrlCrossRefPubMedWeb of Science
  64. 64.
    1. Hayden JT,
    2. Smith N,
    3. Woolf DA,
    4. Barry PW,
    5. O'Callaghan C
    . A randomised crossover trial of facemask efficacy. Arch Dis Child 2004;89(1):72–73.
    OpenUrlAbstract/FREE Full Text
  65. 65.↵
    1. Sangwan S,
    2. Gurses BK,
    3. Smaldone GC
    . Facemasks and facial deposition of aerosols. Pediatr Pulmonol 2004;37(5):447–452.
    OpenUrlCrossRefPubMedWeb of Science
  66. 66.↵
    1. Smaldone GC,
    2. Sangwan S,
    3. Shah A
    . Facemask design, facial deposition, and delivered dose of nebulized aerosols. J Aerosol Med 2007;20(Suppl 1):S66–S77.
    OpenUrlCrossRefPubMedWeb of Science
  67. 67.↵
    1. Janssens HM,
    2. Tiddens HA
    . Aerosol therapy: the special needs of young children. Paediatr Respir Rev 2006;7(Suppl 1):S83–S85.
    OpenUrlCrossRefPubMedWeb of Science
  68. 68.↵
    1. Rubin BK
    . Bye-bye, blow-by. Respir Care 2007;52(8):981.
    OpenUrlFREE Full Text
  69. 69.↵
    1. Pisut FM
    . Comparison of medication delivery by T-nebulizer with inspiratory and expiratory reservoirs. Respir Care 1989;34(11):985–988.
    OpenUrl
  70. 70.↵
    1. Pitance L,
    2. Reychler G,
    3. Leal T,
    4. Reychler H,
    5. Liistro G,
    6. Montharu J,
    7. et al
    . Aerosol delivery to the lung is more efficient using an extension with a standard jet nebulizer than an open-vent jet nebulizer. J Aerosol Med Pulm Drug Deliv 2013;26(4):208–214.
    OpenUrl
  71. 71.↵
    1. Corcoran TE,
    2. Dauber JH,
    3. Chigier N,
    4. Iacono AT
    . Improving drug delivery from medical nebulizers: the effects of increased nebulizer flow rates and reservoirs. J Aerosol Med 2002;15(3):271–282.
    OpenUrlCrossRefPubMedWeb of Science
  72. 72.
    1. Hoffman L,
    2. Smithline H
    . Comparison of Circulaire to conventional small volume nebulizer for the treatment of bronchospasm in the emergency department. Respir Care 1997;42(12):1170–1174.
    OpenUrl
  73. 73.
    1. Mason JW,
    2. Miller WC
    . Comparison of aerosol delivery via circulaire nebulizer system versus a disposable nebulizer in COPD patients. Respir Care 1996;41(11):1006–1008.
    OpenUrl
  74. 74.
    1. Mason JW,
    2. Miller WC,
    3. Small S
    . Comparison of aerosol delivery via circulaire system vs conventional small volume nebulizer. Respir Care 1994;39(12):1157–1161.
    OpenUrl
  75. 75.
    1. Piper SD
    . In vitro comparison of the Circulaire and AeroTee to a traditional nebulizer T-piece with corrugated tubing. Respir Care 2000;45(3):313–319.
    OpenUrlPubMed
  76. 76.↵
    1. Rau JL,
    2. Ari A,
    3. Restrepo RD
    . Performance comparison of nebulizer designs: constant-output, breath-enhanced, and dosimetric. Respir Care 2004;49(2):174–179.
    OpenUrlAbstract/FREE Full Text
  77. 77.↵
    1. Devadason SG,
    2. Everard M,
    3. Linto JM,
    4. Le Souef PN
    . Comparison of drug delivery from conventional versus “Venturi” nebulizers. Eur Respir J 1997;10(11):2497–2483.
    OpenUrl
  78. 78.
    1. Ho SL,
    2. Kwong WT,
    3. O'Drowsky L,
    4. Coates AL
    . Evaluation of four breath-enhanced nebulizers for home use. J Aerosol Med 2001;14(4):467–475.
    OpenUrlCrossRefPubMedWeb of Science
  79. 79.↵
    1. Lin HL,
    2. Fang TP,
    3. Cho HS,
    4. Wan GH,
    5. Hsieh MJ,
    6. Fink JB
    . Aerosol delivery during spontaneous breathing with different types of nebulizers-in vitro/ex vivo models evaluation. Pulm Pharmacol Ther 2018;48(2):225–231.
    OpenUrl
  80. 80.↵
    1. Leung K,
    2. Louca E,
    3. Coates AL
    . Comparison of breath-enhanced to breath-actuated nebulizers for rate, consistency, and efficiency. Chest 2004;126(5):1619–1627.
    OpenUrlCrossRefPubMed
  81. 81.
    1. Newman SP,
    2. Pitcairn GR,
    3. Hooper G,
    4. Knoch M
    . Efficient drug delivery to the lungs from a continuously operated open-vent nebulizer and a low pressure compressor system. Eur Respir J 1994;7(6):1177–1181.
    OpenUrlAbstract
  82. 82.↵
    1. Newnham DM,
    2. Lipworth BJ
    . Nebulizer performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser system (Venstream). Thorax 1994;49(8):762–770.
    OpenUrlAbstract/FREE Full Text
  83. 83.↵
    1. Rau JL
    . Design principles of liquid nebulization devices currently in use. Respir Care 2002;47(11):1257–1275.
    OpenUrlPubMed
  84. 84.↵
    1. Nikander K,
    2. Bisgaard H
    . Impact of constant and breath-synchronized nebulization on inhaled mass of nebulized budesonide in infants and children. Pediatr Pulmonol 1999;28(3):187–193.
    OpenUrlCrossRefPubMed
  85. 85.
    1. Nikander K,
    2. Turpeinen M,
    3. Wollmer P
    . Evaluation of pulsed and breath-synchronized nebulization of budesonide as a means of reducing nebulizer wastage of drug. Pediatr Pulmonol 2000;29(2):120–126.
    OpenUrlCrossRefPubMed
  86. 86.↵
    1. Arunthari V,
    2. Bruinsma RS,
    3. Lee AS,
    4. Johnson MM
    . A prospective, comparative trial of standard and breath-actuated nebulizer: efficacy, safety, and satisfaction. Respir Care 2012;57(8):1242–1247.
    OpenUrlAbstract/FREE Full Text
  87. 87.↵
    1. Sabato K,
    2. Ward P,
    3. Hawk W,
    4. Gildengorin V,
    5. Asselin JM
    . Randomized controlled trial of a breath-actuated nebulizer in pediatric asthma patients in the emergency department. Respir Care 2011;56(6):761–770.
    OpenUrlAbstract/FREE Full Text
  88. 88.↵
    1. Dhand R
    . Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care 2002;47(12):1406–1416.
    OpenUrlPubMed
  89. 89.
    1. Lass JS,
    2. Sant A,
    3. Knoch M
    . New advances in aerosolised drug delivery: vibrating membrane nebuliser technology. Expert Opin Drug Deliv 2006;3(5):693–702.
    OpenUrlCrossRefPubMed
  90. 90.↵
    1. Knoch M,
    2. Keller M
    . The customised electronic nebuliser: a new category of liquid aerosol drug delivery systems. Expert Opin Drug Deliv 2005;2(2):377–390.
    OpenUrlCrossRefPubMed
  91. 91.↵
    1. Ari A
    . Aerosol therapy in pulmonary critical care. Respir Care 2015;60(6):858–874.
    OpenUrlAbstract/FREE Full Text
  92. 92.↵
    1. Gowda AA,
    2. Cuccia AD,
    3. Smaldone GC
    . Reliability of vibrating mesh technology. Respir Care 2017;62(1):65–69.
    OpenUrlAbstract/FREE Full Text
  93. 93.↵
    1. Pitance L,
    2. Vecellio L,
    3. Leal T,
    4. Reychler G,
    5. Reychler H,
    6. Liistro G
    . Delivery efficacy of a vibrating mesh nebulizer and a jet nebulizer under different configurations. J Aerosol Med Pulm Drug Deliv 2010;23(6):389–396.
    OpenUrlPubMed
  94. 94.↵
    1. Ari A,
    2. de Andrade AD,
    3. Sheard M,
    4. AlHamad B,
    5. Fink JB
    . Performance comparisons of jet and mesh nebulizers using different interfaces in simulated spontaneously breathing adults and children. J Aerosol Med Pulm Drug Deliv 2015;28(4):281–289.
    OpenUrlPubMed
  95. 95.↵
    1. Hill NS,
    2. Preston IR,
    3. Roberts KE
    . Inhaled therapies for pulmonary hypertension. Respir Care 2015;60(6):794–802.
    OpenUrlAbstract/FREE Full Text
  96. 96.↵
    1. Nikander K,
    2. Turpeinen M,
    3. Wollmer P
    . The conventional ultrasonic nebulizer proved inefficient in nebulizing a suspension. J Aerosol Med 1999;12(2):47–53.
    OpenUrlPubMedWeb of Science
  97. 97.↵
    1. Singh S,
    2. Kanbar-Agha F,
    3. Sharafkhaneh A
    . Novel aerosol delivery devices. Semin Respir Crit Care Med 2015;36(4):543–551.
    OpenUrl
  98. 98.↵
    1. Zhou QT,
    2. Tang P,
    3. Leung SS,
    4. Chan JG,
    5. Chan HK
    . Emerging inhalation aerosol devices and strategies: where are we headed? Adv Drug Deliv Rev 2014;75:3–17.
    OpenUrlCrossRefPubMed
  99. 99.↵
    1. Denyer J,
    2. Dyche T
    . The adaptive aerosol delivery (AAD) technology: past, present, and future. J Aerosol Med Pulm Drug Deliv 2010;23(Suppl 1):S1–S10.
    OpenUrl
  100. 100.
    1. Byrne NM,
    2. Keavey PM,
    3. Perry JD,
    4. Gould FK,
    5. Spencer DA
    . Comparison of lung deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic fibrosis. Arch Dis Child 2003;88(8):715–718.
    OpenUrlAbstract/FREE Full Text
  101. 101.
    1. Denyer J,
    2. Nikander K,
    3. Smith NJ
    . Adaptive aerosol delivery (AAD) technology. Expert Opin Drug Deliv 2004;1(1):165–176.
    OpenUrlCrossRefPubMed
  102. 102.
    1. Nikander K,
    2. Arheden L,
    3. Denyer J,
    4. Cobos N
    . Parents' adherence with nebulizer treatment of their children when using an adaptive aerosol delivery (AAD) system. J Aerosol Med 2003;16(3):273–281.
    OpenUrlCrossRefPubMed
  103. 103.↵
    1. Van Dyke RE,
    2. Nikander K
    . Delivery of iloprost inhalation solution with the HaloLite, Prodose, and I-neb Adaptive Aerosol Delivery systems: an in vitro study. Respir Care 2007;52(2):184–190.
    OpenUrlAbstract/FREE Full Text
  104. 104.↵
    1. Peters SG
    . Continuous bronchodilator therapy. Chest 2007;131(1):286–289.
    OpenUrlCrossRefPubMed
  105. 105.↵
    1. Salo D,
    2. Tuel M,
    3. Lavery RF,
    4. Reischel U,
    5. Lebowitz J,
    6. Moore T
    . A randomized, clinical trial comparing the efficacy of continuous nebulized albuterol (15 mg) versus continuous nebulized albuterol (15 mg) plus ipratropium bromide (2 mg) for the treatment of acute asthma. J Emerg Med 2006;31(4):371–376.
    OpenUrlCrossRefPubMed
  106. 106.↵
    1. Camargo CA Jr.,
    2. Spooner CH,
    3. Rowe BH
    . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database Syst Rev 2003(4):CD001115.
  107. 107.↵
    1. Hess DR,
    2. Fink JB,
    3. Venkataraman ST,
    4. Kim IK,
    5. Myers TR,
    6. Tano BD
    . The history and physics of heliox. Respir Care 2006;51(6):608–612.
    OpenUrlAbstract/FREE Full Text
  108. 108.↵
    1. Rodrigo GJ,
    2. Castro-Rodriguez JA
    . Heliox-driven beta2-agonists nebulization for children and adults with acute asthma: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2014;112(1):29–34.
    OpenUrl
  109. 109.↵
    1. Hess DR,
    2. Acosta FL,
    3. Ritz RH,
    4. Kacmarek RM,
    5. Camargo CA Jr.
    . The effect of heliox on nebulizer function using a beta-agonist bronchodilator. Chest 1999;115(1):184–189.
    OpenUrlCrossRefPubMedWeb of Science
  110. 110.↵
    1. Corcoran TE,
    2. Gamard S
    . Development of aerosol drug delivery with helium oxygen gas mixtures. J Aerosol Med 2004;17(4):299–309.
    OpenUrlCrossRefPubMedWeb of Science
  111. 111.↵
    1. O'Callaghan C,
    2. White J,
    3. Jackson J,
    4. Crosby D,
    5. Dougill B,
    6. Bland H
    . The effects of heliox on the output and particle-size distribution of salbutamol using jet and vibrating mesh nebulizers. J Aerosol Med 2007;20(4):434–444.
    OpenUrlPubMed
  112. 112.↵
    1. Burchett DK,
    2. Darko W,
    3. Zahra J,
    4. Noviasky J,
    5. Probst L,
    6. Smith A
    . Mixing and compatibility guide for commonly used aerosolized medications. Am J Health Syst Pharm 2010;67(3):227–230.
    OpenUrlAbstract/FREE Full Text
  113. 113.↵
    1. Ari A,
    2. Fink JB,
    3. Dhand R
    . Inhalation therapy in patients receiving mechanical ventilation: an update. J Aerosol Med Pulm Drug Deliv 2012;25(6):319–332.
    OpenUrlPubMed
  114. 114.↵
    1. Dhand R
    . How should aerosols be delivered during invasive mechanical ventilation? Respir Care 2017;62(10):1343–1367.
    OpenUrlAbstract/FREE Full Text
  115. 115.↵
    1. Hess DR
    . Aerosol therapy during noninvasive ventilation or high-flow nasal cannula. Respir Care 2015;60(6):880–891.
    OpenUrlAbstract/FREE Full Text
  116. 116.↵
    1. Berlinski A,
    2. Ari A,
    3. Davies P,
    4. Fink J,
    5. Majaesic C,
    6. Reychler G,
    7. et al
    . Workshop report: aerosol delivery to spontaneously breathing tracheostomized patients. J Aerosol Med Pulm Drug Deliv 2017;30(4):207–222.
    OpenUrl
  117. 117.↵
    1. Standaert TA,
    2. Morlin GL,
    3. Williams-Warren J,
    4. Joy P,
    5. Pepe MS,
    6. Weber A,
    7. et al
    . Effects of repetitive use and cleaning techniques of disposable jet nebulizers on aerosol generation. Chest 1998;114(2):577–586.
    OpenUrlCrossRefPubMed
  118. 118.↵
    1. Melani AS,
    2. Bonavia M,
    3. Cilenti V,
    4. Cinti C,
    5. Lodi M,
    6. Martucci P,
    7. et al
    . Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011;105(6):930–938.
    OpenUrlCrossRefPubMed
  119. 119.↵
    1. Mahler DA,
    2. Waterman LA,
    3. Ward J,
    4. Gifford AH
    . Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate. J Aerosol Med Pulm Drug Deliv 2014;27(2):103–109.
    OpenUrl
  120. 120.↵
    1. Price D,
    2. Roche N,
    3. Virchow JC
    . Device type and real-world effectiveness of asthma combination therapy: an observational study. Respir Med 2011;105:1457–1466.
    OpenUrlPubMed
  121. 121.
    1. Jones R,
    2. Martin J,
    3. Thomas V,
    4. Skinner D,
    5. Marshall J,
    6. Slagno D,
    7. et al
    . The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study. Int J Chron Obstruct Pulmon Dis 2017;12;2445–2454.
    OpenUrl
  122. 122.↵
    1. Dekhuijzen PNR,
    2. Batsiou M,
    3. Bjermer L,
    4. Bosnic-Anticevich S,
    5. Chrystyn H,
    6. Papi A,
    7. et al
    . Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids : effect of drug, dose, and device. Respir Med 2016;120:54–63.
    OpenUrl
  123. 123.↵
    1. Goldin JG,
    2. Tashkin DP,
    3. Kleerup EC,
    4. Greaser LE,
    5. Haywood UM,
    6. et al
    . Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: Assessment with functional helical thin section computed tomography. J Aller Clin Immunol 1999;104(6):S258–S267.
    OpenUrlCrossRefPubMedWeb of Science
  124. 124.↵
    1. Nielsen KG,
    2. Bojsen AK,
    3. Iversen M,
    4. Ifversen M,
    5. Klug B,
    6. Bisgaard H
    . Clinical effect of Diskus dry-powder inhaler at low and high inspiratory flow-rates in asthmatic children. Eur Respir J 1998;11(2):350–354.
    OpenUrlAbstract
  125. 125.↵
    1. Loh CH,
    2. Peters SP,
    3. Lovings TM,
    4. Ohar JA
    . Suboptimal inspiratory flow rates are associated with chronic obstructive pulmonary disease and all cause readmissions. Ann Am Thorac Soc 2017;14(8):1305–1311.
    OpenUrl
  126. 126.↵
    1. Sharma G,
    2. Mayorga VM,
    3. Deering KL,
    4. Harshaw Q,
    5. Ganapathy V
    . Prevalence of low peak inspiratory flow rate at discharge in patients hospitalized for COPD exacerbation. J COPD Found 2017;4(3):217–224.
    OpenUrl
  127. 127.↵
    1. Stevenson NJ,
    2. Walker PP,
    3. Costello RW,
    4. Calverley PMA
    . Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172(12):1510–1516.
    OpenUrlCrossRefPubMedWeb of Science
  128. 128.↵
    1. Broeders ME,
    2. Molema J,
    3. Hop WC,
    4. Vermue NA,
    5. Folgering HT
    . The course of inhalation profiles during an exacerbation of obstructive lung disease. Respir Med 2004;98(12):1173–1179.
    OpenUrlCrossRefPubMedWeb of Science
  129. 129.↵
    1. Bateman ED,
    2. Linnhof AE,
    3. Homik L,
    4. Freudensprung U,
    5. Smau L,
    6. Engelstätter R
    . Comparison of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma. Pulm Pharmacol Ther 2008;21(2):264–275.
    OpenUrlCrossRefPubMed
  130. 130.↵
    1. Derom E,
    2. Van De Velde V,
    3. Marissens S,
    4. Engelstätter R,
    5. Vincken W,
    6. Pauwels R
    . Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′monophosphate in asthmatic patients. Pulm Pharmacol Ther 2005;18(5):328–336.
    OpenUrlCrossRefPubMedWeb of Science
  131. 131.↵
    1. Derom E,
    2. Louis R,
    3. Tiesler C,
    4. Engelstätter R,
    5. Kaufman JM,
    6. Joos GF
    . Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma. Eur Respir J 2009;33(6):1277–1286.
    OpenUrlAbstract/FREE Full Text
  132. 132.
    1. Hoshino M
    . Comparison of effectiveness in ciclesonide and fluticasone propionate on small airway function in mild asthma. Allergol Int 2010;59(1):59–66.
    OpenUrlCrossRefPubMed
  133. 133.↵
    1. Huchon G,
    2. Magnussen H,
    3. Chuchalin A,
    4. Dymek L,
    5. Gonod FB,
    6. Bousquet J,
    7. et al
    . Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med 2009;103(1):41–49.
    OpenUrlCrossRefPubMed
  134. 134.
    1. Papi A,
    2. Paggiaro P,
    3. Nicolini G,
    4. Vignola AM,
    5. Fabbri LM
    , the ICAT SE study group. Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 2007;62(10):1182–1188.
    OpenUrlCrossRefPubMedWeb of Science
  135. 135.↵
    1. Postma DS,
    2. Roche N,
    3. Colice G,
    4. Israel E,
    5. Martin RJ,
    6. van Aalderen WM,
    7. et al
    . Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. Int J Chron Obstruct Pulmon Dis 2014;9:1163–1186.
    OpenUrl
  136. 136.↵
    1. Usmani OS,
    2. Biddiscombe MF,
    3. Barnes PJ
    . Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med 2005;172(12):1497–1504.
    OpenUrlCrossRefPubMedWeb of Science
  137. 137.↵
    1. Zanen P,
    2. Go LT,
    3. Lammers JW
    . Optimal particle size for beta 2agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax 1996;51(10):977–980.
    OpenUrlAbstract/FREE Full Text
  138. 138.↵
    1. Small M,
    2. Anderson P,
    3. Vickers A,
    4. Kay S,
    5. Fermer S
    . Importance of inhaler-device satisfaction in asthma treatment: real-world observations of physician-observed compliance and clinical/patient-reported outcomes. Adv Ther 2011;28(3):202–212.
    OpenUrlCrossRefPubMed
  139. 139.↵
    1. Malmberg LP,
    2. Rytila P,
    3. Happonen P,
    4. Haahtela T
    . Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters. Int J Chron Obstruct Pulmon Dis 2010;5:257–262.
    OpenUrlPubMed
  140. 140.↵
    1. Feddah MR,
    2. Brown KR,
    3. Gipps,
    4. Davies NM
    . In vitro characterization of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates. J Pharm Pharmaceut Sci 2000;3(3):318–324.
    OpenUrlPubMed
  141. 141.↵
    1. Yokohama H,
    2. Yamamura Y,
    3. Oseki T
    . Analysis of relationship between peak inspiratory flow rate and amount of drug delivered to lungs following inhalation of fluticasone propionate with a Diskhaler. Biol Pharm Bull 2007;30(1):162–164.
    OpenUrlPubMed
  142. 142.
    1. Grant AC,
    2. Walker R,
    3. Hamilton M,
    4. Garrill K
    . The ELLIPTA dry powder inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregivers. J Aerosol Med Pulm Drug Deliv 2015;28(6):1–12.
    OpenUrlCrossRefPubMed
  143. 143.↵
    1. Prime D,
    2. de Backer W,
    3. Hamilton M,
    4. Cahn A,
    5. Preece A,
    6. Kelleher D,
    7. et al
    . Effect of disease severity in asthma and chronic obstructive pulmonary disease on inhaler-specific Inhalation profiles through the Ellipta dry powder inhaler. J Aerosol Med Pulm Drug Deliv 2015;28(6):486–497.
    OpenUrl
  144. 144.↵
    1. Buttini F,
    2. Brambilla G,
    3. Copella D,
    4. et al
    . Effect of flow rate on in vitro aerodynamic performance of NEXThaler in comparison with Diskus and Turbohaler dry powder inhalers. J Aerosol Med Pulm Drug Deliv 2016;29(2):167–178.
    OpenUrl
  145. 145.↵
    1. Hamilton M,
    2. Leggett R,
    3. Pang C,
    4. Charles S,
    5. Gillett BD
    . In vitro dosing performance of the ELLIPTA dry powder inhaler using asthma and COPD patient inhalation profiles replicated with the Electronic Lung (eLungTM). J Aerosol Med Pulm Drug Deliv 2015(6):28:1–9.
    OpenUrlCrossRefPubMed
  146. 146.↵
    1. Mahler DA,
    2. Waterman LA,
    3. Gifford AH
    . Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus dry powder inhaler. J Aerosol Med Pulm Drug Deliv 2013;26(3):174–179.
    OpenUrl
  147. 147.↵
    1. Janssens W,
    2. VandenBrande P,
    3. Hardeman E,
    4. De Langhe E,
    5. Philps T,
    6. Troosters T,
    7. Decramer M,
    8. et al
    . Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J 2008;31(1):78–83.
    OpenUrlAbstract/FREE Full Text
  148. 148.↵
    1. Jordanaglou J,
    2. Pride NB
    . A comparison of maximum inspiratory and expiratory flow in health and in lung disease. Thorax 1968;23(1):38.
    OpenUrlAbstract/FREE Full Text
  149. 149.↵
    1. Wade OL,
    2. Gilson JC
    . The effect of posture on diaphragmatic movement and vital capacity in normal subjects with a note on spirometry as an aid in determining radiological chest volumes. Thorax 1951;6(2):103.
    OpenUrlFREE Full Text
  150. 150.↵
    1. Taube C,
    2. Rydzy L,
    3. Eich A,
    4. Corn S,
    5. Kommann S,
    6. Sebastian M,
    7. et al
    . Use of a portable device to record maximum inspiratory flow in relation to dyspnoea in patients with COPD. Respir Med 2011;105:316–321.
    OpenUrlPubMed
  151. 151.↵
    1. Sa RC,
    2. Zeman KL,
    3. Bennett WD,
    4. Prisk GK,
    5. Darquenne C
    . Effect of posture on regional deposition of coarse particles in the healthy human lung. J Aerosol Pulm Drug Deliv 2014;28(6):423–431.
    OpenUrl
  152. 152.↵
    1. Pleasants RA
    . Dry powder inhalers and humidity: another factor to consider to ensure adequate lung delivery. Ann Am Thorac Soc 2017;14(10):1602.
    OpenUrl
  153. 153.↵
    1. Borgstrom L,
    2. Asking L,
    3. Lipiniuas P
    . An in vivo and in vitro comparison of two powder inhalers following storage at hot/humid conditions. J Aerosol Med 2005;18(3):304–310.
    OpenUrlCrossRefPubMed
  154. 154.↵
    1. Janson C,
    2. Loof T,
    3. Telg G,
    4. Stratelis G,
    5. Nilsson F
    . Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study. Prim Care Respir Med 2016;26:16053.
    OpenUrl
  155. 155.↵
    Breo Ellipta package insert. Research Triangle Park, NC: GlaxoSmithKline.
  156. 156.↵
    Seretide Accuhaler package insert. Hertfordshire, UK: GlaxoSmithKline.
  157. 157.↵
    Spiriva Handihaler package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.
  158. 158.↵
    1. Normansell R,
    2. Kew KM,
    3. Mathioudakis AG
    . Interventions to improve inhaler technique for people with asthma. Cochrane Database Syst Rev 2017;3:CD012286.
    OpenUrl
  159. 159.↵
    1. Goodwin R,
    2. Chander T,
    3. Shah N,
    4. Tomlin S
    . Inhaler counselling, the real deal or just fresh air? Arch Dis Child 2016;101(9):e2.
    OpenUrlAbstract/FREE Full Text
  160. 160.↵
    1. Bosnic-Anticevich SZ,
    2. Sinha H,
    3. So S,
    4. Reddel HK
    . Metered-dose inhaler technique: the effect of two educational interventions delivered in community pharmacy over time. J Asthma 2010;47(3):251–256.
    OpenUrlCrossRefPubMedWeb of Science
  161. 161.↵
    1. Takaku Y,
    2. Kurashima K,
    3. Ohta C,
    4. Ishiguro T,
    5. Kagiyama N,
    6. Yanagisawa T,
    7. Takayanagi N
    . How many instructions are required to correct inhalation errors in patients with asthma and chronic obstructive pulmonary disease? Respir Med 2017;123(2):110–115.
    OpenUrl
  162. 162.↵
    1. Chrystyn H,
    2. van der Palen J,
    3. Sharma R,
    4. Barnes N,
    5. Delafont B,
    6. et al
    . Device errors in asthma and COPD: systematic literature review and meta-analysis. NPJ Primary Care Respir Med 2017;27(1):22.
    OpenUrl
  163. 163.↵
    1. Lavorini F,
    2. Levy ML,
    3. Corrigan C,
    4. Crompton G
    , ADMIT Working Group. The ADMIT series – issues in inhalation therapy. 6) Training tools for inhalation devices. Prim Care Respir J 2010;19(4):335–341.
    OpenUrlPubMed
  164. 164.↵
    National Jewish Health. Instructional videos. Available at: https://www.nationaljewish.org/treatment-programs/medications/asthma-medications/devices/instructional-videos. Accessed May 2, 2018.
  165. 165.↵
    1. Mulhall AM,
    2. Zafar MA,
    3. Record S,
    4. Channell H,
    5. Panos RJ
    . A tablet-based multimedia education tool improves provider and subject knowledge of inhaler use techniques. Respir Care 2017;62(2):163–171.
    OpenUrlAbstract/FREE Full Text
  166. 166.↵
    1. Godara N,
    2. Godara R,
    3. Khullar M
    . Impact of inhalation therapy on oral health. Lung India 2011;28(4):272–275.
    OpenUrlPubMed
  167. 167.↵
    1. Gardenhire DS,
    2. Burnett D,
    3. Strickland S,
    4. Myers TR
    . A Guide to Aerosol Delivery Devices for Respiratory Therapists, 4th ed. Irving, Texas: American Association for Respiratory Care; 2017.
  168. 168.↵
    1. Hess DR,
    2. Myers TR,
    3. Rau JL
    . A guide to aerosol delivery devices for respiratory therapists. Irving, Texas: American Association for Respiratory Care; 2005.
Back to top

In this issue

 

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Related Articles

Cited By...

Keywords